MSLN and neoplasm: The platform's adaptability and effectiveness were assessed using an immunoglobulin specific to a fungal laccase to establish the performance of the system, and antibodies against two clinically significant targets‐ mesothelin, a tumor‐associated glycoprotein, and the SARS‐CoV‐2 spike protein‐ to showcase the diagnostic potential of the system.